A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Kaplonek P, Yao L, Reppe K, Voss F, et al. Vaccine 2022;40:1038-1046.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kaplonek P, Yao L, Reppe K, Voss F, et al. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine 2022;40:1038-1046.
PMID: 35033388